Decellularization technology developer MiroMatrix Medical raised $23 million in a new round of equity financing, according to an SEC filing posted last week.
MiroMatrix develops and utilizes a proprietary technology to remove cells, or decellularize, organs and tissue.
Currently, MiroMatrix has 510(k) clearance for its MiroMesh biological mesh used during hernia repair procedures and as a general wound treatment, and plans to submit additional applications for other indications, according to its website.
MiroMatrix plans to pursue other applications of its proprietary technology, including creating a cortical strut, cardiac patch and other regenerative uses, according to the Eden Prairie, Minn.-based company’s site.
The round saw participation form 116 unnamed investors, according to an SEC filing. The company did not indicate if any returning investors cooperated in the round.
The post MiroMatrix raises $23m for decellularizing tech appeared first on MassDevice.
from MassDevice http://ift.tt/1N5vCPa
Cap comentari:
Publica un comentari a l'entrada